CALL - SPRINTER OPEN END - GILEAD SCIENCES | Market Closed - Börse Stuttgart 20:41:55 30/04/2024 BST | ||
| 1.47 EUR | -4.55% |
|
| Current month | -36.36% | ||
| 1 month | -36.36% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 1.47 | -4.55% | 0 |
| 29/04/24 | 1.54 | +0.65% | 0 |
| 26/04/24 | 1.53 | +2.68% | 0 |
| 25/04/24 | 1.49 | -9.70% | 0 |
| 24/04/24 | 1.65 | -2.37% | 0 |
Delayed Quote Börse Stuttgart
Last update April 30, 2024 at 08:41 pm
More quotesStatic data
| Product type | Knock-Out sin Stop Loss |
|---|---|
| Buy / Sell | CALL |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VP9T2G |
| ISIN | DE000VP9T2G1 |
| Date issued | 29/10/2020 |
| Strike | 49.56 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 1.01 € |
| Emission volume | N/A |
| Settlement | Por diferencias |
| Currency | EUR |
Technical Indicators
| Highest since issue | 4.05 € |
|---|---|
| Lowest since issue | 0.88 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
32
Last Close Price
65.94
USD
Average target price
84.1
USD
Spread / Average Target
+27.54%
- Stock Market
- Certificates
- Certificat
